glp 1 agonist uses GLP-1 Receptor Shortage: Challenges and Solutions in Type 2 Diabetes Care The New Weight Management Meds

N Engl J Med 6 392(10):958971 [DOI] [PubMed] 25.Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M

E., & Jordan, J

Reducing fat-driven inflammation Fat tissue releases inflammatory chemicals

The risk of seizure is higher in people who take higher doses of CONTRAVE, have certain medical conditions, or take CONTRAVE with certain other medicines

GLP-1 receptor agonists, offering clinically proven and durable weight-loss outcomes, are thus positioned to capture expanding demand in obesity management, driving market growth globally and complementing their use in diabetes care